[의약품]Apotex Inc./ SmithKline Beecham (Cork) Limited/ Apotex Technologies, Inc/ SmithKline Beecham Limited f/k/a Smithkline Beecham PLC 대 Lupin Ltd./ Lupin Pharmaceuticals, Inc. 간의 의약품 관련 특허 분쟁

발생일자 2015.05.01

사건번호 2:15-cv-00599

법원국가 UNITED STATES OF AMERICA

관할법원명 D.C.E.D.Texas(지방법원)

침해권리 특허

원고명 Apotex Inc./ SmithKline Beecham (Cork) Limited/ Apotex Technologies, Inc/ SmithKline Beecham Limited f/k/a Smithkline Beecham PLC ( 캐나다 / 외국기업 )

피고명 Lupin Ltd./ Lupin Pharmaceuticals, Inc. ( 미국 / 외국기업 )

소송유형 침해금지

분쟁내용

[Apotex Inc. et al v. Lupin Ltd. et al] 사건번호 2:15-cv-00599에 따르면 원고 Apotex Inc./ SmithKline Beecham (Cork) Limited/ Apotex Technologies, Inc/ SmithKline Beecham Limited f/k/a Smithkline Beecham PLC는 피고 Lupin Ltd./ Lupin Pharmaceuticals, Inc.을 상대로 특허 US7229640을 침해하였다는 이유로 미국 텍사스 동부 지방법원에 소를 제기하였다.

분쟁결과 분쟁중

산업분류 화학∙바이오 > 의약품

계쟁제품 12.5 mg, 25 mg and 37.5 mg - paroxetine hydrochloride controlled

지재권번호/명칭

US7229640 Paroxetine controlled release compositions

Paroxetine controlled release compositions

Abstract

A controlled release or delayed release formulation contains a selective serotonin reuptake inhibitor (SSRI) such as paroxtine.

What is claimed is:

1. A composition, that reduces the incidence of nausea and vomiting associated with the administration of paroxetine, comprising paroxetine, or a pharmaceutically acceptable salt thereof, in a controlled and delayed release swallow pharmaceutical formulation that, upon administration, releases the paroxetine predominantly in the small intestine.

2. A method of treating one or more disease states selected from; Alcoholism, Anxiety, Depression, Obsessive Compulsive Disorder, Panic Disorder, Chronic Pain, Obesity, Senile Dementia, Migraine, Bulimia, Anorexia, Social Phobia, Pre-Menstrual Syndrome (PMS), Adolescent Depression, Trichotillomania, Dysthymla and Substance Abuse, which comprises administering an effective amount of a controlled and delayed release swallow pharmaceutical formulation that, upon administration, releases paroxetine or a pharmaceutically acceptable salt thereof, predominantly in the small intestine to an individual in need thereof. 

   출처